XBIO — Xenetic Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$4.23
+$0.04 (+0.95%)
Xenetic Biosciences Inc (XBIO) is a biotechnology company listed on NASDAQ. It is led by James F. Parslow, based in 945 Concord Street, Framingham, MA, United States, 01701, with about 2 employees. Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Latest reported XBIO revenue for 2025-09-30 was $1.0M. Net income was -$509.9K. Revenue was up 74.1% from 2025-06-30 to 2025-09-30. XBIO currently screens at market cap $5.7M.
Use this XBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Xenetic Biosciences Inc even when a live quote feed is slow.
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
XBIO Key Statistics
Market Cap
$5.71M
Volume
27,346
Previous Close
$3.81
Day Range
$3.58 – $3.82
EPS
-$2.57
Revenue
$2.50M
Net Income
-$3.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-1.6%
Profit Margin
-158.4%
Employees
2
XBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.50M | $2.54M | $1.71M | $1.16M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.96M | -$4.13M | -$6.55M | -$5.65M |
| EPS (Diluted) | -$2.57 | -$2.71 | -$4.61 | -$0.55 |
Total Assets
$6.90M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$6.17M
Operating Cash Flow
-$2.82M
Free Cash Flow
$0.00
Xenetic Biosciences Inc Company Information
- CFO, COO, Interim CEO & Corporate Secretary
- James F. Parslow
- Headquarters
- 945 Concord Street, Framingham, MA, United States, 01701
- Website
- www.xeneticbio.com
- Phone
- 781 778 7720
- IPO / Founded
- 2014-06-30
- Sector
- Healthcare
- Industry
- Biotechnology